We're Micro‑Poisoning Ourselves—Biohacker Slams America's $5T Health Spending
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
38 minutes ago
- Yahoo
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
New York Times
41 minutes ago
- New York Times
UnitedHealth's Profits Fall as Costs of Care Continue to Rise
UnitedHealth Group, the giant health care conglomerate, said on Tuesday that it continued to struggle with higher-than-anticipated costs of providing medical care to patients enrolled in its health plans, reporting a drop in earnings for the quarter ended June 30. While UnitedHealth remained profitable, its operating earnings for the three months fell to $5.2 billion from $7.9 billion in the same period of 2024. Revenues, however, increased to $111.6 billion for the three months of 2025, compared with $98.9 billion for the same period of 2024. The higher costs were felt across the company's vast health insurance operations, including one of its most successful businesses, selling private Medicare plans as an alternative to traditional Medicare. UnitedHealth owns the nation's largest health insurer, UnitedHealthcare, which covers 50 million people. Other insurance companies have also reported rising medical costs and disappointing profits. Last Friday, Centene, a for-profit insurance company that focuses mostly on patients who are enrolled in Medicaid and Obamacare plans, was the latest insurer to blame rising expenses for poor financial results. But UnitedHealth's stumble, which began earlier this year, has shocked many of its investors who have come to rely on steady increases of profits from the conglomerate. Since November, the company's stock has lost roughly half of its value. The company owns an assortment of health care businesses, including surgery centers, a vast network of medical practices, and a big pharmacy benefit manager as well as health insurance plans. In the new earnings report, UnitedHealth acknowledged that many of the businesses housed under its Optum unit were also underperforming, including its network of physicians and other clinicians who provide care under the privatized portion of the Medicare program, known as Medicare Advantage. UnitedHealth has experienced a series of misfortunes over the last two years, including the murder of the chief executive of its insurance operations, Brian Thompson. Investors have lost confidence in the company's business model, and patients have grown increasingly frustrated with its methods. In May, it abruptly replaced its chief executive, Andrew Witty, with Stephen Hemsley, who had stepped down from the position in 2017. Last week, the company confirmed the Department of Justice was investigating its Medicare operations. UnitedHealth announced its earnings before the stock market opened. Mr. Hemsley took steps to reassure investors. The company, which had withdrawn its profit outlook for the year, provided investors with an estimate of what it expected to earn for 2025. It estimated revenues of slightly under $450 billion with net earnings of at least $14.65 per share. The company said it expected to return to earnings growth in 2026. 'UnitedHealth Group has embarked on a rigorous path back to being a high-performing company fully serving the health needs of individuals and society broadly,' Mr. Hemsley said in a statement in the company's earnings release. 'As we strengthen operating disciplines, positioning us for growth in 2026 and beyond, the people at UnitedHealth Group will continue to support the millions of patients, physicians and customers who rely on us, guided by a culture of service and longstanding values.'
